Clinical relevance of host immunity in breast cancer: From TILs to the clinic

Nature Reviews Clinical Oncology

Volumn 13, Issue 4, 2016, Pages 228-241

  Savas, Peter ^a   Salgado, Roberto ^b   Denkert, Carsten ^c   Sotiriou, Christos ^b   Darcy, Phillip K ^a   Smyth, Mark J ^d   Loi, Sherene ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b JULES BORDET INSTITUTE   (Belgium)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; DISEASE ASSOCIATION; DISEASE MARKER; EARLY CANCER; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOSTIMULATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANIMAL; BREAST TUMOR; FEMALE; IMMUNITY; IMMUNOLOGY; METABOLISM; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNITY; LYMPHOCYTES, TUMOR-INFILTRATING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS;

EID: 84949844816     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.215     Document Type: Review

References (130)

1. Underwood, J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br. J. Cancer 30, 538-548 (1974
2. Tsuyuguchi, I., Shiratsuchi, H., & Fukuoka, M. T lymphocyte subsets in primary lung cancer. Jpn J. Clin. Oncol. 17, 13-17 (1987
3. Sistrunk, W. E., & Maccarty, W. C. Life expectancy following radical amputation for carcinoma of the breast: a clinical and pathologic study of 218 cases. Ann. Surg. 75, 61-69 (1922
4. Tang, R. P., et al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J. Cell. Biochem. 44, 189-198 (1990
5. Whitford, P., George, W. D., & Campbell, A. M. Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. Cancer Lett. 61, 157-164 (1992
6. Chin, Y., et al. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 12, 1463-1466 (1992
7. Schwartzentruber, D. J., Topalian, S. L., Mancini, M., & Rosenberg, S. A. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-Alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J. Immunol. 146, 3674-3681 (1991
8. Tanaka, H., Watanabe, M., Zeniya, M., & Takahashi, H. Ultrastructure of IL2 stimulated tumor-infiltrating lymphocytes showing cytolytic activity against tumor cells. Acta Pathol. Jpn 41, 94-105 (1991
9. Schwartzentruber, D. J., Solomon, D., Rosenberg, S. A., & Topalian, S. L. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J. Immunother. 12, 1-12 (1992
10. Baxevanis, C. N., et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74, 1275-1282 (1994
11. Dadmarz, R., Sgagias, M. K., Rosenberg, S. A., & Schwartzentruber, D. J. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class II restricted fashion. Cancer Immunol. Immunother. 40, 1-9 (1995
12. Degnim, A. C., et al. Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Res. Treat. 144, 539-549 (2014
13. Gouon-Evans, V., Rothenberg, M. E., & Pollard, J. W. Postnatal mammary gland development requires macrophages and eosinophils. Development 127, 2269-2282 (2000
14. Tuaillon, E., et al. Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. J. Immunol. 182, 7155-7162 (2009
15. Ruffell, B., et al. Leukocyte composition of human breast cancer. Proc. Natl Acad. Sci. USA 109, 2796-2801 (2012
16. Willard-Gallo, K., et al. The significance of tumor infiltrating lymphocyte density, subset composition and organization in breast cancer [abstract] Cancer Res. 75, aPD1-3 (2015
17. Yamaguchi, R., et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum. Pathol. 43, 1688-1694 (2012
18. Loi, S., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860-867 (2013
19. Ali, H. R., et al. Association between CD8+ T cell infiltration and breast cancer survival in 12 439 patients. Ann. Oncol. 25, 1536-1543 (2014
20. Schmidt, M., et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin ? C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 18, 2695-2703 (2012
21. Ignatiadis, M., et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30, 1996-2004 (2012
22. Salgado, R., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259-271 (2014
23. Gu Trantien, C., et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873-2892 (2013
24. Denkert, C., et al. Tumor-Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105-113 (2010
25. Nawaz, S., Heindl, A., Koelble, K., & Yuan, Y. Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Mod. Pathol. 28, 766-777 (2015
26. Loi, S. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J. Clin. Oncol. 32, 2935-2937 (2014
27. Polley, M. Y. C., et al. An international Ki67 reproducibility study. J. Natl Cancer Inst. 105, 1897-1906 (2013
28. Van de Pavert, S. A., & Mebius, R. E. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10, 664-674 (2010
29. Brown, M., & Wittwer, C. Flow cytometry: principles and clinical applications in hematology. Clin. Chem. 46, 1221-1229 (2000
30. Stack, E. C., Wang, C., Roman, K. A., & Hoyt, C. C. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70, 46-58 (2014
31. Denkert, C., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2 positive and triple-negative primary breast cancers. J. Clin. Oncol. 33, 983-991 (2015
32. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015
33. Cortazar, P., et al. Pathological complete response and long-Term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164-172 (2014
34. Tan, M. C., et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am. J. Surg. 198, 520-525 (2009
35. Kraus, J. A., et al. Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 20, 334-339 (2012
36. Kurozumi, S., et al. ER, PgR, Ki67, 27Kip1, and histological grade as predictors of pathological complete response in patients with HER2 positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide conco. BMC Cancer 15, 622 (2015
37. Simon, R. M., Paik, S., & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101, 1446-1452 (2009
38. Loi, S., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544-1550 (2014
39. Adams, S., et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32, 2959-2966 (2014
40. Salgado, R., et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2 positive early-stage breast cancer treated with lapatinib and trastuzumab. JAMA Oncol. 1, 448 (2015
41. Obeid, M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007
42. Mattarollo, S. R., et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71, 4809-4820 (2011
43. Issa-Nummer, Y., et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2 negative breast cancer-A substudy of the neoadjuvant GeparQuinto trial. PLoS ONE 8, e79775 (2013
44. West, N. R., et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 13, R126 (2011
45. Dieci, M., et al. Tumor infiltrating lymphocytes and correlation with outcome in the Cher-LOB study [abstract] Cancer Res. 75, aPD1-1 (2015
46. Loi, S., et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2 positive breast cancer (HER2+ BC) [abstract] Cancer Res. 73, aS1-05 (2013
47. Demaria, S., et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 7, 3025-3030 (2001
48. Horlock, C., et al. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T cell axis in patients with breast cancer. Br. J. Cancer 100, 1061-1067 (2009
49. Ladoire, S., et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin. Cancer Res. 14, 2413-2420 (2008
50. Dieci, M. V., et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann. Oncol. 25, 1-8 (2014
51. Loi, S., et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD 1/PD L1 immune checkpoint inhibitors. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-15-1125 (2015
52. Garc?a-Mart?nez, E., et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 16, 488 (2014
53. Robbins, P. F., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013
54. Linnemann, C., et al. High-Throughput epitope discovery reveals frequent recognition of neo-Antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85 (2014
55. Tran, E., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014
56. Schreiber, R. D., Old, L. J., & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011
57. Rajasagi, M., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124, 453-462 (2014
58. Wang, Y., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 1-15 (2014
59. Yadav, M., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014
60. Granados, D. P., et al. Impact of genomic polymorphisms on the repertoire of human MHC class I associated peptides. Nat. Commun. 5, 3600 (2014
61. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012
62. Denizot, F., Wilson, A., Battye, F., Berke, G., & Shortman, K. Clonal expansion of T cells: a cytotoxic T cell response in vivo that involves precursor cell proliferation. Proc. Natl Acad. Sci. USA 83, 6089-6092 (1986
63. Langhoff, E., & Steinman, R. M. Clonal expansion of human T lymphocytes initiated by dendritic cells. J. Exp. Med. 169, 315-320 (1989
64. Marchingo, J. M., et al. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion. Science 346, 1123-1127 (2014
65. Mlecnik, B., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 6, 228ra37 (2014
66. Ye, J., et al. Specific recruitment of ?d regulatory T cells in human breast cancer. Cancer Res. 73, 6137-6148 (2013
67. Diamond, M. S., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989-2003 (2011
68. Fuertes, M. B., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8a+ dendritic cells. J. Exp. Med. 208, 2005-2016 (2011
69. Woo, S. R., et al. The STING pathway mediates innate immune sensing of immunogenic tumors. Immunity 41, 830-842 (2014
70. Hansen, M. H., Nielsen, H. V., & Ditzel, H. J. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J. Immunol. 169, 2701-2711 (2002
71. Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59-73 (2008
72. Apetoh, L., et al. Toll-like receptor 4 dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007
73. Ghiringhelli, F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL 1b dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009
74. Spranger, S., et al. Up regulation of PD L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013
75. Gros, A., et al. PD 1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246-2259 (2014
76. Read, S., Malmstrφm, V., & Powrie, F. Cytotoxic T lymphocyte-Associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000
77. Krummel, M. F., & Allison, J. P. CD28 and CTLA 4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995
78. Leach, D. R., Krummel, M. F., & Allison, J. P. Enhancement of antitumor immunity by CTLA 4 blockade. Science 271, 1734-1736 (1996
79. Hodi, F. S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
80. Dong, H., et al. Tumor-Associated B7 H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002
81. Robert, C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015
82. Wolchok, J. D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013
83. Schalper, K. A., et al. In situ tumor PD L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin. Cancer Res. 20, 2773-2782 (2014
84. Motz, G. T., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615 (2014
85. Shrimali, R. K., et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180 (2010
86. Gramaglia, I., Weinberg, A. D., Lemon, M., & Croft, M. Ox 40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161, 6510-6517 (1998
87. Vu, M. D., et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 110, 2501-2510 (2007
88. Ruby, C. E., et al. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J. Immunol. 183, 4853-4857 (2009
89. Curti, B. D., et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189-7198 (2013
90. Monney, L., et al. Th1 specific cell surface protein Tim 3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536-541 (2002
91. Sakuishi, K., et al. Targeting Tim 3 and PD 1 pathways to reverse T cell exhaustion and restore anti-Tumor immunity. J. Exp. Med. 207, 2187-2194 (2010
92. Ngiow, S. F., et al. Anti TIM3 antibody promotes T cell IFN ? mediated antitumor immunity and suppresses established tumors. Cancer Res. 71, 3540-3551 (2011
93. Sakuishi, K., et al. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T cell dysfunction in cancer. Oncoimmunology 2, e23849 (2013
94. Huang, Y. H., et al. CEACAM1 regulates TIM 3 mediated tolerance and exhaustion. Nature 517, 386-390 (2014
95. Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P., & Munn, D. H. Cells expressing indoleamine 2, 3 dioxygenase inhibit T cell responses. J. Immunol. 168, 3771-3776 (2002
96. Qian, F., et al. Efficacy of levo 1 methyl tryptophan and dextro-1 methyl tryptophan in reversing indoleamine 2, 3 dioxygenase-mediated arrest of T cell proliferation in human epithelial ovarian cancer. Cancer Res. 69, 5498-5504 (2009
97. US National Library of Medicine. NCT01792050. ClinicalTrials.gov [online], http//:www.clinicaltrials.gov/ct2/show/NCT01792050 (2015
98. US National Library of Medicine. NCT02048709. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT02048709 (2015
99. Antonioli, L., Blandizzi, C., Pacher, P., & Hasks, G. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13, 842-857 (2013
100. Loi, S., et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl Acad. Sci. USA 110, 11091-11096 (2013
101. Stagg, J., et al. Anti CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107, 1547-1552 (2010
102. Beavis, P. A., et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl Acad. Sci. USA 110, 14711-14716 (2013
103. Beavis, P. A., et al. Adenosine receptor 2A blockade increases the efficacy of anti PD 1 through enhanced antitumor T cell responses. Cancer Immunol. Res. 3, 506-517 (2015
104. Hauser, R. A., et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 13, 767-776 (2014
105. Emens, L., et al. Inhibition of PD L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer [abstract] Cancer Res. 75, aPD1-6 (2015
106. Wolchok, J. D., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009
107. US National Library of Medicine. NCT02425891. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT02425891 (2015
108. Nanda, R., et al. A Phase Ib study of pembrolizumab (MK 3475) in patients with advanced triple-negative breast cancer [abstract] Cancer Res. 75, aS1-09 (2015
109. US National Library of Medicine. NCT02447003. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT02447003 (2015
110. Vonderheide, R. H., et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-Associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16, 3485-3494 (2010
111. Postow, M. A., Callahan, M. K., & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974-1982 (2015
112. Stagg, J., et al. Anti-ErbB 2 mAb therapy requires type I and II interferons and synergizes with anti PD 1 or anti CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142-7147 (2011
113. US National Library of Medicine. NCT02129556. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT02129556 (2015
114. Verbrugge, I., et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72, 3163-3174 (2012
115. Dewan, M. Z., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA 4 antibody. Clin. Cancer Res. 15, 5379-5388 (2009
116. Twyman-Saint Victor, C., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015
117. US National Library of Medicine. NCT02303366. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT02303366 (2015
118. Eggermont, A. M., et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial [abstract] J. Clin. Oncol. 32, aLBA9008 (2014
119. Herbst, R. S., et al. Predictive correlates of response to the anti PD L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014
120. Tumeh, P. C., et al. PD 1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014
121. Velcheti, V., et al. Programmed death ligand 1 expression in non-small cell lung cancer. Lab. Invest. 94, 107-116 (2014
122. Larkin, J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015
123. Sharma, P., & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015
124. Quezada, S. A., et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125-2138 (2008
125. Rizvi, N. A., et al. Mutational landscape determines sensitivity to PD 1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015
126. Van Allen, E. M., et al. Genomic correlates of response to CTLA 4 blockade in metastatic melanoma. Science 350, 207-211 (2015
127. Savas, P. S., et al. Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2 positive breast cancer (HER2+ BC) [abstract] J. Clin. Oncol. 33, a613 (2015
128. Cimino-Mathews, A., Ye, X., Meeker, A., Argani, P., & Emens, L. A. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum. Pathol. 44, 2055-2063 (2013
129. Kawai, O., et al. Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113, 1387-1395 (2008
130. Joyce, J. A., & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80 (2015